[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.197.114. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
February 24, 1997

A Case of Prader-Willi Syndrome With Long-term Mazindol Treatment

Author Affiliations

Kobe, Japan

Arch Intern Med. 1997;157(4):464. doi:10.1001/archinte.1997.00440250124020
Abstract

Prader-Willi syndrome is a disorder characterized by obesity, hypogonadism, hypotonia, and mental retardation, which is genetically caused by a deletion of a small part of chromosome 15 in some, but not all, patients.1-4 Obesity is associated with diabetes mellitus of the maturity-onset type. The hyperphagia associated with Prader-Willi syndrome is severe and chronic and is responsible for the early mortality of people with the condition. The hyperphagia, together with the behavioral difficulties, makes Prader-Willi syndrome one of the most serious and pervasive conditions with respect to its impact on the family unit.

Report of a Case.  We treated a male patient with Prader-Willi syndrome and overt diabetes mellitus for which he took insulin; we found that the addition of a small dose of mazindol to the insulin therapy was effective in preventing hyperglycemic coma. At the time of the initial mazindol administration, the patient was 23 years old and

First Page Preview View Large
First page PDF preview
First page PDF preview
×